Welcome to our dedicated page for Centene Del SEC filings (Ticker: CNC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Centene Corporation (NYSE: CNC) SEC filings, offering insight into the company’s regulatory disclosures, financial communications, and governance updates. As a healthcare enterprise focused on government-sponsored and commercial healthcare programs, Centene uses filings such as Form 8-K to inform investors about material events, earnings information, and board changes.
Recent 8-K filings describe Centene’s participation in healthcare investor conferences, where management discusses the company’s financial outlook and the use of non-GAAP financial measures like adjusted diluted earnings per share. Other 8-Ks report quarterly financial results, the withdrawal or update of earnings guidance, and the resignation of directors along with resulting changes in the size of the board. These documents help investors understand how Centene evaluates its performance, plans operations, and manages corporate governance.
Through this filings page, users can review Centene’s current and historical submissions to the U.S. Securities and Exchange Commission, including annual and quarterly reports when available, as well as event-driven filings. Real-time updates from EDGAR are combined with AI-powered summaries that explain the key points of complex documents, helping readers interpret financial metrics, non-GAAP reconciliations, and narrative disclosures without wading through every page.
In addition to financial information, Centene’s filings may address topics such as regulatory considerations, risk factors related to government healthcare programs, and the company’s approach to non-GAAP reporting. For investors tracking CNC, this page serves as a central location to monitor new filings, understand the context of earnings announcements, and follow changes in leadership or guidance as they are formally reported to the SEC.
Centene Corp director Kenneth Tanji reported receiving a grant of 1,179 shares of Common Stock as a compensation-related award. The shares were acquired at no purchase price, increasing his direct holdings to 7,917 shares. Ownership includes 3,579 restricted stock units that are subject to vesting requirements.
Samuels Theodore R. II reported acquisition or exercise transactions in this Form 4 filing.
Centene Corp director Theodore R. Samuels II received a grant of 943 shares of Common Stock as a stock award. The award was recorded at a price of $0.00 per share and increased his directly held stake to 20,755.979 shares.
He also has indirect ownership of 32,000 shares through a revocable family trust where he serves as co-trustee. Ownership further includes 3,579 shares of restricted stock units that are subject to vesting requirements.
EPPINGER FREDERICK H reported acquisition or exercise transactions in this Form 4 filing.
Centene Corporation director Frederick H. Eppinger reported receiving a grant of 1,690 shares of common stock, recorded at $0.00 per share as a compensation-related award, not an open-market purchase. Following this grant, he directly holds 362,050.658 common shares.
A footnote states that this ownership figure also includes 5,965 shares of restricted stock units that are subject to vesting requirements, meaning those shares will be delivered only if the vesting conditions are met.
COUGHLIN CHRISTOPHER J reported acquisition or exercise transactions in this Form 4 filing.
Centene Corp director Christopher J. Coughlin received an equity award of 1,140 shares of common stock on March 31, 2026. The shares were granted at no cash cost as a stock-based compensation award, increasing his directly held common stock to 14,156.926 shares.
He also has indirect ownership of 30,054 shares held by a grantor retained annuity trust for the benefit of Mr. Coughlin and his adult children, where he serves as sole trustee. His direct ownership includes 3,579 restricted stock units that remain subject to vesting requirements.
Centene Corp executive Theodore J. Pienkos, Corporate Controller and Chief Accounting Officer, filed an initial ownership report showing 29,843.4930 shares of common stock held directly. This total includes 16,140 restricted stock units that vest in scheduled installments between September 15, 2026 and March 15, 2027.
The ownership also includes 1,381 performance stock units reported at target level, granted on March 15, 2024. The number of these performance units that will actually vest on March 15, 2027 can range from 0% to 200% of the target amount, depending on achievement of performance conditions.
Centene Corp: The Vanguard Group amends Schedule 13G to report zero beneficial ownership. The filing (Amendment No. 14) states amount beneficially owned: 0 and percent of class: 0% after an internal realignment; subsidiaries and business divisions will report separately in reliance on SEC Release No. 34-39538 (January 12, 1998).
Centene Corporation is asking stockholders to vote at its 2026 annual meeting on electing nine directors, approving executive pay on an advisory basis, ratifying KPMG as auditor, and a stockholder proposal the Board opposes.
The proxy highlights a challenging 2025, with total revenues of $194.8 billion, a diluted loss per share of $13.53 and adjusted diluted EPS of $2.08, as Medicaid volatility and a sicker Marketplace risk pool pressured results. Management describes corrective actions in pricing, risk management and portfolio focus across Medicaid, Medicare Advantage and Marketplace businesses.
Centene expects 2026 adjusted diluted EPS to exceed $3.00, implying more than 40% year-over-year growth, and points to double-digit improvements in key clinical metrics and strong call-center satisfaction scores. The Board emphasizes governance features such as annual director elections, majority voting, proxy access, a largely independent and refreshed board, and a pay-for-performance compensation design with rigorous stock ownership requirements.
Centene Corporation appointed Theodore Pienkos, 44, as Corporate Controller and Chief Accounting Officer effective March 18, 2026. He is a registered CPA and has served as Centene’s Deputy Corporate Controller since August 2024, after prior roles including Vice President of Finance & Accounting and earlier accounting positions at the company.
Before joining Centene in 2011, he worked as an auditor at KPMG LLP and holds BA and MA degrees in Accounting from the University of Northern Iowa. In his new role, he will receive a base salary of $440,000 and a target bonus of 60% of base salary, and will continue to participate in Centene’s incentive and executive severance programs.
The company also named Kate Casso, the prior Corporate Controller and Chief Accounting Officer, as Senior Vice President, Finance Operations and Innovation effective March 18, 2026, where she will focus on finance operations, data analytics, medical economics, payment integrity, and broader innovation initiatives.
Centene Corp Chief Operating Officer handles tax withholding on vested stock units. Susan Raye Smith reported a disposition of 2,918 shares of Centene common stock at $34.45 per share, described as shares withheld to cover taxes when previously granted restricted stock units vested. This was not an open-market sale. After the withholding, she directly holds 212,720 shares, including 182,815 shares of restricted stock units and performance stock units that remain subject to vesting conditions.
Centene Corp Chief People Officer Tanya M. McNally had 2,785 shares of common stock withheld at $34.45 per share to cover taxes due on the vesting of previously granted restricted stock units. This was an automatic tax-withholding disposition, not an open-market sale.
After this transaction, she directly owns 128,222 shares of Centene common stock. Footnote disclosure states that this ownership figure includes 114,503 shares represented by previously granted restricted stock units and performance stock units, reported at target performance levels and still subject to vesting requirements.